CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Europe set to open lower as Democratic sweep fuels AI regulation fears

By Reuters News

Nov 4 (Reuters) - European shares were likely to open lower on Wednesday, with tech stocks in focus after Democrats won control of both chambers of the US Congress, fuelling concerns that tighter AI regulation could dampen investment in a sector that has driven much of the recent rally.

Futures tracking the STOXX 600 were down about 0.2% by 0639 GMT, having recouped some losses following a 1.4% slide during Asian trade.

Contracts tracking the German DAX dipped about 0.2%, while those of UK's FTSE 100 lost 0.4%.

Democrats captured majorities in both the Senate and House on Tuesday, scoring victories in conservative bastions including South Carolina and Texas, delivering a scathing rebuke to US President Donald Trump.

The result weighed on global equities, as investors feared that stricter oversight of data centre construction, which has already faced resistance in the US, could make AI companies more cautious about spending on the technology.

While technology companies account for only about 7% of the STOXX index, the sector .SX8P has posted the third-strongest gains so far this year, behind energy and chemicals, supported by robust demand for AI infrastructure.

Companies linked to AI-related spending, including equipment makers such as Siemens Energy ENR1n.DE and Schneider Electric SCHN.PA will also be in focus.

Elsewhere, Novo Nordisk NOVOb.CO is likely to gain attention after the Wegovy maker reported third-quarter adjusted operating profit above expectations and raised its full-year sales and profit forecasts.

Investors will keep a close eye on the broader healthcare sector as they weigh prospects of increased US regulation around drug pricing.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.